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Abstract.  We have used an antibody probe to measure 
the levels of topoisomerase II in several transformed 
and developmentally regulated normal cell types. 
Transformed cells contain roughly 1  ×  106 copies of 
the enzyme. During erythropoiesis in chicken embryos 
the enzyme level drops from 7.8  ×  104 copies per 
erythroblast to <300 copies per erythrocyte concomi- 
tant with the cessation of mitosis in the blood. Cul- 
tured myoblasts also lose topoisomerase II upon fusion 
into nonproliferating myotubes. When peripheral blood 
lymphocytes (which lack detectable topoisomerase II) 
commence proliferation, they express topoisomerase II 
de novo. Appearance of the enzyme exactly parallels 
the onset of DNA replication.  These results suggest 
that topoisomerase II is not required for transcription 
in higher eukaryotes, but that it may function during 
DNA replication.  Furthermore, topoisomerase II is a 
sensitive and specific marker for proliferating cells. 
T 
OPOISOMERASES are enzymes that alter the topologi- 
cal state of DNA.  These enzymes relax supercoiled 
DNA  by transient protein-linked cleavages  of either 
one (type I enzymes) or both (type II enzymes) DNA strands 
(31, 55). Type II topoisomerases also catenate and decatenate 
closed circular duplex DNA. The mechanisms of enzyme ac- 
tion have been studied extensively in vitro (31, 55). In con- 
trast, the role of the eukaryotic enzymes in vivo has been 
amenable to analysis only recently, since the development of 
specific antibody probes (3, 12, 18) and the isolation of condi- 
tional lethal mutants in yeasts (6,  19, 53). 
Type II topoisomerases have been implicated in several 
aspects of DNA metabolism and structure, including replica- 
tion (26, 37), sister chromatid exchange (39, 45), transcrip- 
tion (22, 33), organization of  chromosomal loop domains (4, 
17), and chromosome disjunction at mitosis (6, 24, 35, 48, 
49, 53, 54).  In addition, topoisomerase II may be an impor- 
tant structural protein since it is a major component of mi- 
totic chromosome scaffold (9, 12, 18) and interphase nuclear 
matrix (3) fractions. In mitotic chromosomes the enzyme is 
apparently concentrated at the base of the radial loops (9). 
This was the location predicted by the radial loop model of 
chromosome architecture for proteins involved in establish- 
ment and/or maintenance of loop structure (28). 
Genetic studies in yeasts suggest that the major essential 
function of topoisomerase II is to allow chromosomal dis- 
junction (6, 24, 53, 54).  Topoisomerase II mutants remain 
viable at the restrictive temperature, provided that mitosis is 
blocked by inhibitors of microtubule polymerization (24). 
Thus, while topoisomerase II may be involved in other cellu- 
lar processes in yeasts, topoisomerase I can evidently substi- 
tute to carry out these functions if necessary (6, 19, 53, 54). 
In the course of our earlier studies, we observed that the 
levels of topoisomerase II (detected by indirect immunofluo- 
rescence) appeared to vary widely from cell to cell (12). Use 
of a  fluorescence-activated cell  sorter  indicated that cells 
with reduced levels of the antigen consistently had a prerep- 
licative (Gi) DNA content (12). However,  only a small per- 
centage of the Gl cells was negative for topoisomerase II. 
This suggested that either the antigen might be degraded for 
a brief interval during G~, or that the negative cells might 
no longer be dividing. 
A possible link between topoisomerase II activity and cell 
proliferation has been suggested by studies in which enzyme 
activity is  measured  in  proliferating and growth-arrested 
cells. Duguet et al. (7) showed that the low level of enzyme 
activity in liver increased significantly after partial hepatec- 
tomy. Tandou et al. (50) found a low level of enzyme activity 
in Go guinea pig lymphocytes that increased dramatically 
after mitogenic stimulation. A  third study, using Chinese 
hamster ovary (CHO) cells recovering from serum starva- 
tion-induced Go arrest,  found that drug-induced cleavable 
DNA complexes (thought to form in vivo due to inhibition 
of the topoisomerase II religation reaction) increased 4-6 h 
after the onset of DNA synthesis (47). 
Unfortunately, activity assays are sensitive to factors, such 
as efficiency  of enzyme solubilization and cell cycle variabil- 
ity in  specific activity, that cannot be  quantified without 
specific antibody. We therefore decided to rigorously test the 
hypothesis that topoisomerase II  is  a  specific  marker for 
proliferating cells  by examining a  number  of systems in 
which the proliferative activity of defined populations of 
cells undergoes  a  programmed developmental change.  In 
erythropoiesis and myogenesis, blast cells cease  dividing 
concomitant with terminal differentiation. During lympho- 
cyte activation, resting (Go) cells are  induced to divide in 
response to specific stimuli. In all three cases, the processes 
occur with a high degree of natural synchrony. The immuno- 
logical assay that we have used to detect topoisomerase II 
provides an accurate measure of the total cellular level of ac- 
cumulated polypeptide. 
We  found that topoisomerase II is an abundant protein 
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topoisomerase II were greatly reduced when cells ceased 
proliferation.  This  occurred  not  only  in  quiescent  cells 
(erythrocytes), but in cells that remained transcriptionally 
active (myotubes). In contrast, circulating peripheral blood 
lymphocytes, which initially lacked detectable topoisomer- 
ase II, were found to express the antigen de novo following 
mitogenic  stimulation  in  vitro.  In  these  cells,  levels  of 
topoisomerase II rose coordinately with the onset of DNA 
replication, consistent with our earlier observation that cells 
lacking  topoisomerase II  had  a  prereplicative (G1) DNA 
content. Our findings provide strong support for the concept 
that topoisomerase II is a specific marker for proliferating 
cells. 
Materials and Methods 
Buffers 
The following buffers were used. D-PBS contained 8.06  mM Na:HPO,, 
1.47 mM KH2PO4 (pH 7.5),  137 mM NaC1,  and 2.7 mM KCI. Buffer A 
contained 15 mM Tris/HC1 pH 7.4,  80 mM KC1, 2 mM K-EDTA, 0.5 mM 
spermidine, and 0.2 mM spermine plus 8.5%  sucrose. Buffer 3 contained 
5 mM Tris/HCl, pH 7.4, 2 mM KC1, 2 mM K-EDTA, and 0.25 mM spermi- 
dine plus 8.5 % sucrose. 
Immunoprecipitation and Quantitation of 
Topoisomerase H 
Immunoadsorption and gel analysis was carried out essentially as described 
by Ottaviano and Gerace (38). Ceil solubilization buffer also included 2 mM 
I~-mercaptoethanol,  1 mM phenylmethylsulfonyl fluoride (PMSF), and  1 
lag/ml each of chymostatin and antipain. In addition, aliquots (e.g., 2 %) of 
the immunoprecipitate and resultant cell supernatant were analyzed by im- 
munoblotting to determine the efficiency of immunoadsorption. The ratio 
of topoisomerase II in supernatant to pellet (which varied between 20 and 
0.2) was used in the quantitation calculations. 
Isolation and Processing  of  Avian Erythrocytes 
Blood cells were collected from severed embryonic vessels into ice-cold 
D-PBS containing 1 mM EDTA,  1 mM PMSF, and 0.1% Trasylol. Blood 
was obtained from adult chickens by bleeding from the wing vein. Cells 
were washed three times by pelleting at 1,000 g. At this point, aliquots of 
cells were spun through PBS at 400 g onto concanavalin A-treated cover- 
slips (14). Concanavalin A (Calbiochem-Behring Corp., Indianapolis, IN) 
was dissolved at 0.5 mg/ml in 150 mM NaCl, 10 mM Tris, pH 7.4, 0.5 mM 
MnC12, and 0.5 mM CaCI2 to increase stability.  Coverslips were processed 
for immunofluorescence as described (13) with the modification that, after 
permeabilization in 0.1% Triton X-100, KB (wash and antibody dilution 
buffer) contained 0.02 % Triton X-100. After bemacytometer counting, cells 
were pelleted, sonicated, and boiled in SDS sample buffer (12). 
Erythroid cell samples (typically  1-2  x  l06 cells/lane) were electro- 
phoresed in  multiple  10%  polyacrylamide gels (30).  After transfer  to 
nitrocellulose (51) in the presence of  0.1% SDS, blots were processed as de- 
scribed (10) with primary antibody and iodinated protein A. Quantitation 
was done by densitometric scanning of appropriate preflashed autoradio- 
graphic exposures. Alternatively, nitrocellulose blots were stained for 10 
min  in  D-PBS containing 0.3%  Tween-20 and  1  gl/m/  India  ink  (21). 
Desired regions were then excised and quantitated in a gamma counter. 
In Vitro Myogenesis 
11- or 12-d chick embryo thighs were collected into warm DME and dis- 
sected free of bones and overlying skin. After gentle mincing, tissue clumps 
were dissociated in 0.05%  trypsin and 0.25 mM EDTA for 30 rain at 37°C 
with  intermittent pipetting to  facilitate  dissociation.  Trypsinization was 
stopped by the addition of horse serum to 10 %, and cells were washed twice 
in DME +  10% horse serum +  5% embryo extract (27). Cells were plated 
onto gelatin coated glass coverslips at a density of 2  ×  106 cells/60 mm 
dish, and the medium changed after 24 h at 37 ° in a humidified 5% COz 
incubator.  Immunofluorescence was performed as described above. 
Autoradiographic Analysis of Transcription 
4-d  myotube  cultures  were  incubated  with  50  pCi/ml  5,6-[3H]uridine 
(Amersham Corp., Arlington Heights, IL; 48 Ci/mmol) for 3 h. After a 20- 
min chase in medium without label,  coverslips were processed for im- 
munolabeling with the substitution of strepavidin: horse radish peroxidase 
conjugate (Bethesda Research Laboratories, Gaithersburg,  MD)  for the 
usual  fluorescent streptavidin:  Texas  Red  conjugate.  Diaminobenzidine 
served as the reaction substrate. Coverslips were mounted cell side up on 
microscope slides with Krazy-glue and dipped in NTB-2 (Kodak).emulsion 
diluted 1:1  with H20.  Slides were developed in D-19 (Kodak) developer. 
Exposure times were typically on the order of 4 d. To obtain bright field 
images that contained all the desired information (i.e., autoradiographic 
grains, topoisomerase II localization, and cytoplasmic visualization), slides 
were stained with 0.05%  toluidine blue in 0.1% NaB4OT:10 H20 for 20- 
30 s and rinsed in water. Images were photographed on an Olympus Vanox 
AH-2 microscope (S plan apo 60X N.A.  1.40 lens) on Kodak EL400 film 
with exposure times of 1-3 s. 
Avian Lymphocyte  Isolation and Culture 
Lymphocytes were isolated from heparinized peripheral blood by a differen- 
tial centrifugation method as described in Hovi et al. (25). White blood cells 
were cultured at a density of 5  x  106 cells/m/in RPMI 164.0 (pH 7.4) con- 
mining 10 mM HEPES (pH 7.4), 5% fetal calf serum, 2 mM glutamine, 100 
U/ml penicillin, 100 ~tg/ml streptomycin, and 50 ~tM 13-mercaptoethanol. 
Mitogens (PHA-M form,  Gibeo,  Grand Island,  NY  or concanavalin A, 
ICN, Plainview, NY) were added at time 0 at dilutions of 1:50 or 5 I.tg/ml, 
respectively  (and  were  present  throughout  the  experiment).  Methyl- 
[3H]thyrnidine  (Amersham Corp.; 87 Ci/mmol) was added also at time 0 
for replication studies at 0.5 or 1 lxCi/ml. Incorporation of label into DNA 
was assayed by TCA precipitation. At appropriate time points, 0.4 ml of cul- 
ture (2  ×  106 cells) were pelleted in an Eppendorf microfuge and solubi- 
lized in SDS sample buffer.  The presence of topoisomerase II was assayed 
by immunofluorescence (cells attached to concanavalin  A-treated coverslips) 
and by immunoblotting of the protein gel samples. 
Results 
Measurement of Topoisomerase H Levels in 
Normal and Transformed Cells 
We have determined the amount of total cellular topoisomer- 
ase II in two transformed cell lines (MSB-1 and line 249) and 
one normal cell population (5-d erythroblasts) by quantita- 
tive immunoprecipitation. Topoisomerase II immunoprecip- 
itates from a known number of cells were subjected to SDS- 
PAGE.  The amount of precipitated protein was determined 
by elution of the Coomassie Blue from excised gel slices fol- 
lowed  by  spectrophotometry  (16). Absorbance  measure- 
ments were converted to protein mass units by comparison 
with  values  obtained  from  known  amounts  of BSA elec- 
trophoresed in the same gel (see Materials and Methods). 
The results of a typical experiment, in which total cellular 
proteins were solubilized and immunoprecipitated with anti- 
topoisomerase II, are shown in Fig.  1. A single precipitated 
polypeptide of 170 kD was observed in samples exposed to 
specific antibody, and was absent from controls exposed to 
preimmune serum.  Quantitation of the amount of precipi- 
tated 170-kD polypeptide demonstrated that topoisomerase II 
is a very abundant protein in these cells (Table I). The two 
transformed  lines  contained  ,~106 copies  of enzyme/cell 
(Table I). Chicken erythroblasts (5 d) contained 7.5  x  104 
copies. Because these cells already show a 50% decrease in 
topoisomerase II level, as we show below, we calculate that 
the early proliferating erythroblasts have at least 1.5  x  105 
copies of enzyme per cell. The higher values obtained for 
transformed cells may reflect the greater proliferative activ- 
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topoisomerase  II  from  5-d  em- 
bryonic erythroid precursors. 2 ~tl of 
guinea pig  preimmune  (P)  or im- 
mune (I) serum (12) was added to 5 x 
107 solubilized cells. Immune com- 
plexes were sedimented after the ad- 
dition of fixed Staphylococcus aure- 
us, solubilized in SDS sample buffer, 
and electrophoresed in a 10% poly- 
acrylamide gel. The gel was stained 
with Coomassie Blue. The immune 
precipitate  contained  only  topoiso- 
merase II (170 kD),  and the  heavy 
(hc) and light (lc) chains of the im- 
munoglobulins. 
ity of these cells compared with the nontransformed erythro- 
blasts. 
A similar Coomassie-binding method was independently 
used to estimate the amount of topoisomerase II in human 
(HeLa)  mitotic  chromosomes  and  chromosome  scaffolds 
(18).  In  that  study,  total  protein  from chromosomes and 
scaffolds was subjected to SDS PAGE. The authors then used 
the dye-elution assay to determine the amount of a  170-kD 
polypeptide (inferred to be solely topoisomerase II).  That 
study yielded a number (2.8  x  10S/cell) slightly lower than 
those we obtained by immunoprecipitation. This difference 
could reflect either a lower level of the enzyme in HeLa cells 
or losses of antigen incurred during the isolation of chromo- 
somes by Gasser et al.  (18). 
Erythropoiesis  in Chicken Embryos 
Erythropoiesis in the chicken embryo has been widely used 
for the study of the regulation of patterns of gene expression 
during differentiation. Cells of the embryonic mesenchyme 
give rise  to  "primitive" (first generation) proerythroblasts 
that divide and mature in the circulating blood (32, 56). Be- 
tween 2 and 5 d, the circulating red cells are limited to this 
primitive cohort, which differentiates with natural synchrony 
(32, 42).  At 3-4 d of embryogenesis, the blood contains a 
uniform population of primitive polychromatic erythroblasts 
(32). These cells are mitotically active in the blood for the 
first 8 d of development (42; this study, data not shown). 
At later times (6-8 d), the situation is more complex, and 
mature primitive erythrocytes coexist in the blood with late 
"definitive" polychromatic erythroblasts. These populations 
are difficult to distinguish, as the nuclei of mature primitive 
erythrocytes lack the oblate shape and extensive heterochro- 
matin  that  characterize  the  nuclei  of  mature  definitive 
erythrocytes. From 8 d onward, these early generations are 
progressively superceded by the mature definitive erythro- 
Table L Numbers of Topoisomerase H Monomers per 
Cell in Several Cell Types 
Number of 
Cell type  Number of copies  determinations 
MSB-1  lymphoblastoid  1.6  +  0.81  x  106  15 
249  hepatoma  7.6  4-  3.4  x  lO  s  3 
5-d erythroblasts  7.8  4-  1.6  x  104  6 
Values are derived from quantitation of the amount of 170-kD polypeptide that 
could  be immunoprecipitated  from a known number of cells (Materials  and 
Methods). 
cytes, and the composition of the blood again becomes effec- 
tively uniform at  10 d of embryogenesis (42). 
Analysis of  Erythroid Cells by Immunofluorescence 
Blood was obtained from developing embryos at 3 d (and at 
intervals of  24 h thereafter) and red cells separated from con- 
taminating yolk platelets by gentle centrifugation. An aliquot 
of the cells was processed for indirect immunofluorescence, 
and the remainder was boiled directly in SDS sample buffer 
for subsequent electrophoresis (see next section). To mini- 
mize possible proteolysis, all steps were performed in the 
presence of trasylol,  PMSF,  chymostatin, leupeptin,  anti- 
pain, and pepstatin. 
At 3-4 d development, virtually all (99%) primitive poly- 
chromatic erythroblasts contained levels of topoisomerase II 
readily detected by indirect immunofluorescence (Fig.  2, 
a-c). In erythroblasts, as in cultured cells (12), the antigen 
was localized in nuclei and mitotic chromosomes. Shortly 
thereafter, the percentage of immunopositive cells began to 
decline, and by 6 d development, only 53 % of the cells con- 
tained detectable levels of antigen (Fig. 2, d-f). 
The percentage of immunopositive cells dropped rapidly 
during subsequent development, reaching 2 % at 10 d. From 
10 to  18 d this percentage remained constant (Fig. 2, g-i). 
Immunopositive ceils were independently recognizable un- 
der phase contrast, since they had larger, more euchromatic 
nuclei  (Fig.  2  h).  These  are  apparently  rare  circulating 
erythroblasts that persist late into development (H.  Wein- 
traub, personal communication). Blood from a chick (15 d 
post-hatching) or adult chicken contained no erythroid cells 
positive for topoisomerase II by immunofluorescence (not 
shown). 
These  results  suggest  that  topoisomerase II  disappears 
from erythroid cells concomitant with the loss of prolifera- 
tive ability. 
Detection of Topoisomerase H in Erythroid Cells 
by Immunoblotting 
Since results obtained by immunofluorescence depend on ac- 
cessibility of the antigens to the antibody, we also examined 
the cells for the presence of topoisomerase II by immuno- 
blotting techniques. In each experiment, isolated blood cells 
were subjected to SDS PAGE in parallel gels.  One gel was 
stained with Coomassie Blue (Fig. 3 a) and the others elec- 
trotransferred to nitrocellulose. In all cases, samples derived 
from an equal number of cells were loaded in each lane. 
Since a decrease in cell volume by ,'~70  % accompanies the 
initial stages of erythroid maturation (42), the total amount 
of protein per lane decreased over the course of the experi- 
ment (Fig.  3 a). 
Heck and Earnshaw  Topoisomerase  H: A  Specific  Marker for Cell Proliferation  2571 Figure 2. Immunofluorescent visualization of topoisomerase II in isolated chicken embryonic erythroid cells. Cells were attached by cen- 
trifugation onto concanavalin A-treated  coverslips and processed for immunofluorescence. Embryonic age is indicated for each series of 
images beneath the panel. Phase contrast (a, d, and g), DAPI staining of DNA (b, e, and h), and topoisomerase II localization (c, f, and 
i). Bar, 10 ¢m. 
Control blots were probed with a serum specific for eryth- 
rocyte [3-tubulin  (gift of Dr.  Douglas Murphy, Johns Hop- 
kins University) and with a human autoantibody recognizing 
topoisomerase I  (44).  The amounts of tubulin and topoiso- 
merase I decreased during maturation by •65  % (Fig. 3 b), 
and 62 % (Fig. 4),  respectively. Therefore the ratio of both 
proteins to cell volume remained approximately constant. 
A significantly different pattern was observed when simi- 
lar nitrocellulose blots were probed with antiserum to topo- 
isomerase II (Fig. 3 c). In this case, the antibody binding de- 
creased dramatically over time.  The data of Fig.  3  c  were 
quantified by densitometry of multiple prefogged films ex- 
posed for appropriate times. The levels of topoisomerase II 
present in erythroid cells from day 3 onward are presented 
in Fig. 5. Approximately 50% of the initial binding was lost 
between days 4 and 5, and a basal level of 2 % was reached 
by  day  10.  This  low  level  of binding  remained  constant 
throughout  the  second  half of embryogenesis  and  corre- 
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total  extracts  from  embryonic  and  adult  erythroid 
cells. Cells (1.25  x  106/lane) were washed in PBS 
containing protease inhibitors at 4°C, lysed by boiling 
and sonicating in sample buffer,  and electrophoresed 
in 10%  polyacrylamide gels.  (A) Coomassie Blue- 
stained gel. (B and C) Nitrocellulose transfers from 
gels run in parallel probed with (B) an erythrocyte- 
specific antibody to 13-tubulin and (C) anti-topoiso- 
merase II. Bound antibody was visualized by autora- 
diography with 125I-protein  A. Embryonic age in days 
is indicated at the bottom. M is blood from an adult 
(mature) chicken. The mobilities of standard proteins 
(myosin, 200 kD; beta-galactosidase, 116 kD; phos- 
phorylase b, 95 kD; bovine serum albumin, 68 kD; 
catalase, 60 kD; actin, 43 kD; aldolase, 40 kD; car- 
bonic anhydrase, 29 kD) are indicated to the left of A. 
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Figure  5.  Quantitation  of the  loss  of topoisomerase  II  during 
chicken erythropoiesis. Appropriate exposures of immunoblots like 
that of Fig. 3 were scanned with an integrating densitometer. The 
density of both cleaved and intact topoisomerase II were included. 
These values are represented as the percent of binding normalized 
to the 3-d value (solid circles).  The percentage of immunopositive 
cells at each time point (measured by indirect innnunofluorescence) 
is also designated (x). From 10 d onward, the level of embryonic 
topoisomerase II remains constant at 2 % (equal to the percentage 
of immunopositive cells). Adult chicken erythrocytes (designated 
M at right of the figure) contain no topoisomerase II detectable by 
either immunofluorescence or immunoblotting. 
Figure 4. Detection of topoisomerase I in erythroid cells by immu- 
noblotting. Total  cell extracts were prepared and analyzed as in Fig. 
2. The nitrocellulose blot was probed with a human autoimmune 
serum recognizing topoisomerase I. Numbers at the top indicate the 
embryonic age in days. M, adult chicken erythrocytes (1.9 x  10  6 
cells were loaded per lane). Arrowheads indicate the position of the 
molecular weight standards (as in Fig. 2). 
sponded precisely to the percentage of cells containing topo- 
isomerase II  detectable by  immunofluorescence (Fig.  2). 
This suggests that the antigen detected in immunoblots arose 
from the rare circulating erythroblasts. 
We could not detect topoisomerase II in mature chicken 
erythrocytes, even in overexposed immunoblots from lanes 
loaded with 4  x  106  mature erythrocytes. In contrast,  in 
parallel experiments we have detected topoisomerase II from 
as few as 750 MSB-1  cells. Given our estimation of 1.6  × 
106 copies/MSB-1 cell, we conclude that the mature eryth- 
rocyte has an upper limit of 300 copies of the enzyme per 
cell. 
Such  conclusions  from  immunoblotting  experiments 
could be  influenced by  two  potentially serious  concerns. 
First, the antitopoisomerase II antiserum (which was raised 
against the scaffold-associated form of the enzyme) might 
detect only a subfraction of the total topoisomerase II. We 
believe this to be unlikely, since an independent antiserum 
raised against purified topoisomerase II from bovine calf thy- 
mus  (20)  gave identical results in immunoblotting experi- 
ments (data not shown). Differences in cross-species immu- 
noreactivity between these two antisera argue strongly that 
they recognize different epitopes on the protein. Second, ma- 
ture  red  cells  might  contain  proteases  that  degrade  the 
topoisomerase II during preparation of the gel samples. We 
have attempted to minimize this possibility by use of a mix- 
ture of  protease inhibitors during the cell isolation steps, and 
by disruption of the cells directly in boiling  SDS  sample 
buffer (Materials and Methods).  Using this procedure, we 
did not detect immunoreactive proteolytic fragments of ei- 
ther topoisomerase I, ~tubulin, or histone H5 in immuno- 
blots. Moreover, in additional experiments we have assayed 
for topoisomerase H-specific protease activity by mixing a 
constant number of MSB-1 cells with increasing numbers of 
ll-d erythrocytes  (in ratios up to 1:125). When these mixtures 
were  processed  for  immunoblotting  as  above,  the  total 
amount of topoisomerase II remained constant at all ratios 
tested.  Taken together,  these  results  suggest that  the dis- 
appearance of  topoisomerase II does not result from the pres- 
ence of high levels of nonspecific proteases in the mature 
erythroid cells. 
Both antitopoisomerase II antibodies showed significant 
binding to a  protein band of ~29  kD  (Fig.  3  c).  Since it 
cofractionated with nuclei and was therefore a candidate for 
being a stable erythroid-specific breakdown product of topo- 
isomerase II,  the identity of this  antigen was  investigated 
further.  The following four observations (data not shown) 
suggest that this antigen is not a proteolytic fragment of  topo- 
isomerase II, but rather is histone H5, and that the binding 
of antibodies to it is nonspecific. (a) The 29-kD polypeptide 
was excised from a preparative polyacrylamide gel and in- 
jected into two guinea pigs. Both animals produced antibod- 
ies that recognized the antigen in immunoblots. One of these 
antisera also stained the nuclei of erythroid cells at all stages 
of development in indirect immunofluorescence. (b) Neither 
antibody showed detectable binding to topoisomerase II in 
immunoblots. However both antibodies strongly recognized 
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University of California, Berkeley) in similar experiments. 
(c) Bona fide histone H5 was not immunoprecipitated by the 
topoisomerase II antibody. (d) We have previously observed 
artefactual histone binding by other antibodies against chro- 
mosomal  nonhistone  proteins  using  our  immunoblotting 
protocol (10, 13). The degree of  binding varies, depending on 
the protocols used for washing the blots, and is probably due 
to the highly positively charged nature of the histones. We 
conclude that the 29-kD polypeptide is most probably his- 
tone H5 and is unrelated to topoisomerase II. 
Thus, detection of  total cellular topoisomerase II by immu- 
noblotting confirms that the antigen is lost from embryonic 
erythroid cells concomitant with the cessation of cell di- 
vision. 
Loss of Topoisomerase H during  Myogenesis 
We next wished to determine whether loss of topoisomerase 
II was correlated with the cessation of proliferation or with 
the progressive loss of transcriptional activity that occurs 
during erythropoiesis. Several indirect observations (22, 33) 
suggest that transcription might require torsional strain of  the 
template, presumably due to action of a type II topoisomer- 
ase. This question has been approached by examining two 
cell types (myotubes formed by cell fusion in vitro and hepa- 
tocytes from adult liver). Although each of these cell types 
no longer divides, both retain a high degree of  transcriptional 
activity. 
For culturing myoblasts, single cell suspensions rich in 
myoblasts and fibroblasts were obtained from thighs of ll-d 
chicken embryos. When plated at a  suitable density, myo- 
blasts fused to form myotubes after ,03 d in culture. Nuclei 
in myotubes no longer divide, but continue to actively tran- 
scribe the genes required for muscle function (23).  The as- 
sembly of sarcomeres in these myotubes was confirmed by 
indirect immunofluorescence with a monoclonal antibody to 
myosin  (gift  of Dr.  Thomas  D.  Pollard,  Johns  Hopkins 
School of Medicine; data not shown). Myotube development 
proceeded normally under these conditions, since the syn- 
cytia eventually began to spontaneously contract, often re- 
sulting in their detachment from the culture dish. 
When myoblast cultures were analyzed by immunofluores- 
cence 2 d after plating, virtually all cells were immunoposi- 
tive for topoisomerase II (Fig. 6, a-c). Fusion of myoblasts 
into myotubes was associated with loss of detectable topo- 
isomerase II antigen. At 4 d postplating none of the myotube 
nuclei contained detectable topoisomerase II antigen, while 
many  surrounding  fibroblasts  remained  immunopositive 
(Fig. 6, d-f). In particular, dividing cells were consistently 
found to react strongly with the antibody. In no case were 
nuclei within syncytia found to contain detectable topoiso- 
merase II. 
To confirm that the myotube nuclei were transcriptionally 
active under our experimental conditions, we pulse-labeled 
fused cultures (4 d postplating) with [3H]uridine  and per- 
formed simultaneous immunolocalization and autoradiogra- 
phy. This was done by replacing the streptavidin/Texas  Red 
conjugate  used  for  indirect  immunofluorescence with  a 
streptavidin/horse radish peroxidase conjugate. To enhance 
the contrast of the cytoplasm, slides were also briefly stained 
with toluidine blue. The brown peroxidase reaction product 
and black silver grains were then photographed simultane- 
ously under bright field illumination (Fig. 7). All fibroblasts 
exhibited transcriptional activity, but varied in topoisomer- 
ase II content, with a few negative cells distributed among 
the majority of positive cells.  In all cases,  the clustered 
nuclei of myotubes (marked m) were covered by silver grains 
indicative of transcriptional activity and did not contain de- 
tectable levels of topoisomerase II. 
This  fnding,  taken  together  with  the  observation  that 
nuclei from hepatocytes were negative for topoisomerase II 
when assayed by both immunofluorescence  and immunoblot- 
ting (data not shown), indicates that the reduction in amount 
of  topoisomerase II that accompanies terminal differentiation 
has no apparent effect on the ability of cells to transcribe 
RNA. 
Appearance of Topoisomerase H 
during Lymphocyte  Activation 
There is direct evidence that a type H topoisomerase is re- 
quired for DNA replication in prokaryotes (26, 37). In addi- 
tion, indirect evidence suggests that the enzyme might fulfill 
a similar role in eukaryotes (6, 47-50, 54).  To test whether 
the stoichiometric amounts of topoisomerase II detected by 
our antibody are required for DNA synthesis in eukaryotic 
cells, we measured topoisomerase II levels after mitogenic 
activation of peripheral blood lymphocytes. This approach 
has advantages that (a) before stimulation the level of DNA 
synthesis is negligible, and (b) stimulated cells begin repli- 
cating as a relatively synchronous wave. Thus, it is possible 
to separate events of late G1 and of mitosis from those of S 
phase. 
It is well known that peripheral blood lymphocytes (in Go 
phase) may be stimulated to enter the cell cycle in response 
to an immunological challenge in vivo or in response to a 
number of mitogens in vitro. Since phytohemagglutinin and 
concanavalin A are strict T cell mitogens, they were chosen 
for these studies in order to maximize the synchrony of the 
response. 
Chicken peripheral  blood lymphocytes, when first iso- 
lated, were found not to express topoisomerase II antigen in 
amounts detectable by immunofluorescence (Fig. 8, a-c) or 
immunoblotting.  However,  after  72  h  in  culture,  antigen 
could be detected in 5-30% of the cells (Fig. 8, d-f). These 
results were confirmed by immunoblotting experiments (data 
not shown), which indicated that the appearance of the anti- 
gen reflected de novo protein synthesis in response to the 
onset of proliferation. While the efficiency of stimulation 
showed slight variability between experiments, the overall 
pattern of  the results remained constant. Similar results were 
obtained with both mitogens. 
To examine the temporal relationship between the appear- 
ance of topoisomerase II and the onset of DNA replication, 
activation was carded out in the presence of trace amounts 
of [3H]thymidine.  Incorporation of label into acid insoluble 
products  was  determined at appropriate  intervals.  At the 
same time, known numbers of cells were solubilized in SDS 
sample buffer for immunoblotting and aliquots were pro- 
cessed for indirect immunofluorescence. 
In each experiment, aliquots were taken at 2-h intervals 
beginning at 20 h. Replication was first detected at ,028 h 
after plating. Aliquots taken at 0, 3, 6, 9, and 18 h after the 
onset of replication were processed  for indirect immuno- 
fluorescence and immunoblotting. Though the immunoblot- 
Heck and Earnshaw Topoisomerase  ll: A Specific Marker for Cell Proliferation  2575 Figure 6. The fate of topoisomerase II during in vitro myogenesis as visualized by immunofluorescent staining with antitopoisomerase II. 
2 d after plating (a-c), almost all myoblasts  and fibroblasts contain topoisomerase II. 4-d cultures (d-f) contain extensive myotubes. Nuclei 
of myotubes lack detectable topoisomerase II. Phase-contrast images (a, d), DAPI staining of DNA (b, e) and immunofluorescent localiza- 
tion of topoisomerase II (c, f). Bar, 20 ~tm. 
ting experiments provided a measure of the total accumula- 
tion of  antigen in the culture, the level of  antigen in individual 
cells is not known. 
Few, if any, immunopositive cells were detected before the 
initiation of replication (Fig. 9). Instead, the percentage of 
immunopositive cells  rose  concomitant with  the  onset  of 
DNA synthesis as did the appearance of antigen as detected 
by immunoblotting (not shown). Given the small percentage 
of cells that became detectably immunopositive, this empha- 
sizes the sensitivity of the immunoblotting approach. 
In other experiments, aliquots of cells taken 0,  2, 4  and 
22 h after the onset of replication were processed for autora- 
diography  and  immunolocalization  of  topoisomerase  II. 
These cells were pulsed with 5  IICi/ml  [3H]thymidine for 
30 min before harvesting. Simultaneous detection of replica- 
tion  and  antigen  in  individual  cells  confirmed the  above 
The Journal of Cell Biology, Volume 103,  1986  2576 Figure  7.  Demonstration  of 
transcriptional activity in myo- 
tube  nuclei  lacking  detect- 
able  topoisomerase  II.  m, 
myotube. All other cells are fi- 
broblasts. Before fixation for 
immunolabeling by the perox- 
idase method (brown reaction 
product),  cells were exposed 
to [3H]uridine to detect tran- 
scriptional activity (3-h pulse, 
20-min  chase).  Note  that 
while  all  cells  exhibit  silver 
grains (black), topoisomerase 
II  content  varies.  Myotube 
nuclei  were  always negative 
for  the  antigen. Two  fibro- 
blasts  negative for  topoiso- 
merase  II  are  indicated (ar- 
rowheads).  All  others  show 
varying amounts of the anti- 
gen. Slides were briefly stained 
with toluidine blue to enhance 
cytoplasmic  contrast.  Bar, 
50 ~tm. 
results, that is, virtually all (295/300) S phase cells had de- 
tectable levels of topoisomerase II. No cells were observed 
in which topoisomerase II could be detected in the absence 
of DNA synthesis until very late times, when it was expected 
that many of the cells would have progressed into (32 phase. 
These results suggest that stoichiometric amounts of topo- 
isomerase II do not accumulate late in G~ before the initia- 
tion of replication and confirm our earlier observation that 
all S-phase cells contain detectable levels of the antigen. 
Discussion 
An important insight into the possible role(s) of topoisomer- 
ase II in higher eukaryotes came from the observation of 
Sundin and Varshavsky (48, 49) that the terminal stages of 
SV40 replication involve production of multiply intertwined 
catenated circles which are apparently resolved by a type II 
topoisomerase. They also suggested that the enzyme might 
perform a similar function in chromosome disjunction at mi- 
tosis  (49).  Recent analyses of mutants  defective for topo- 
isomerase II in Saccharomyces  (6,  19,  24) and Schizosac- 
charomyces  (53,  54),  as well as a  detailed analysis of the 
topoisomerase II (gyr B) mutants in Escherichia  coli (46), 
support the initial hypothesis of Sundin and Varshavsky.  Un- 
fortunately, unambiguous analysis of yeast mutants has been 
complicated by the apparent ability of topoisomerases I and 
II to substitute for each other in vivo. This functional redun- 
dancy has prevented genetic dissection from clearly estab- 
lishing the role of the enzymes in transcription and repli- 
cation. 
Genetic approaches in yeasts have been complemented by 
immunobiochemical studies in higher eukaryotes. Topoiso- 
merase II has been shown to be a component of two highly 
insoluble protein fractions from chromosomes and nuclei: 
the mitotic chromosome scaffold (12, 18) and the interphase 
nuclear matrix (3). While it remains for future experiments 
to demonstrate whether the insolubility of these subcellular 
fractions in vitro arises from their being derived from pre- 
existing structures in vivo, these observations suggest that 
topoisomerase II might be an integral structural component 
of the nucleus. 
Recent observations suggesting that the genome of eukary- 
otes  is  constrained  into  topological  domains  containing 
roughly 100 kb (reviewed in reference 8) offer one possible 
structural role for topoisomerase II-i.e., the enzyme might 
be one of the nonhistone components responsible for topo- 
logical  closure  of the  domains.  In  a  previous  stud.y, we 
showed that topoisomerase II  is  apparently  located at the 
base of the radial loops of mitotic chromosomes (9).  Evi- 
dence that the enzyme is similarly positioned in interphase 
nuclei comes from studies of specific DNA fragments that 
remain associated with the nuclear matrix/scaffold fraction 
using the method of Mirkovitch et al. (34). High resolution 
mapping  studies  indicate that such attached fragments are 
significantly enriched in topoisomerase II consensus cleav- 
age sequences (4,  17, 43). 
Using antibodies to measure total topoisomerase II poly- 
peptide,  we  have  shown  that  rapidly  proliferating  trans- 
formed cells contain ~1  ×  106 copies of the enzyme. This 
amount of enzyme is similar to the number of individual nu- 
clear lamin polypeptides found in the peripheral lamina of 
rat liver nuclei (L. Gerace, personal communication). The 
levels of topoisomerase II measured by immunoprecipitation 
are thus consistent with the enzyme fulfilling a structural role 
in organizing the genome. Since the chicken genome is 2.4 
×  l09 bp (or ~2.4  x  l04 100 kb loop domains), there are 
~20  topoisomerase  II  dimers  per  domain  (roughly  one 
dimer per 25 nucleosomes). Alternatively, the interphase ge- 
Heck and Earnshaw Topoisomerase 11: A Specific Marker  for Cell Proliferation  2577 Figure 8. Appearance of topoisomerase II during in vitro activation of chicken lymphocytes. Isolated peripheral blood lymphocytes were 
cultured in the presence of phytohemagglutinin. At 24 h (a-c) or 72 h (d-f) after initiation of culture aliquots of cells were centrifuged 
onto coverslips and processed  for indirect immunofluorescence. Phase-contrast  (a, d), DAPI staining of DNA (b, e), and visualization 
of topoisomerase II (c, f). Immunopositive cells appear in the stimulated culture at 26-30 h.  Bar, 10 ~tm. 
nome could be constrained in domains as small as 5 kb (as- 
suming that topoisomerase II is found at the base of each 
loop). This is the inferred size of the loop domains recently 
determined for the histone gene cluster of Drosophila  (17). 
Earlier  reports  suggested that  topoisomerase II activity 
correlates  with  cell  proliferation  (7,  47,  50),  but  another 
study (52) found no such correlation. However, these studies 
relied solely upon activity assays. As such,  the results had 
to be interpreted  with caution  since they might not reflect 
changes in the total amount of enzyme, but could arise from 
both alterations in the attachment of the enzyme to scaffold/ 
matrix components (affecting the solubilization efficiency), 
and variations in specific activity occurring across the cell 
cycle  [(15); the  latter  may  result  from  posttranslational 
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Figure 9. Topoisomerase I1 antigen appears concurrent with the on- 
set of DNA synthesis. Stimulated lymphocyte cultures (as in Fig. 
8) were grown in the presence of 0.5 IxCi/ml [3H]thymidine. At 
the indicated times, aliquots were taken and incorporation of label 
into acid insoluble material was determined (stars). At appropriate 
time points aliquots were processed for indirect immunofluores- 
cence as in Fig. 8. Random fields were photographed, and the per- 
centage of immunopositive cells determined (solid circles).  Each 






modifications (1)]. Therefore, we have reexamined the rela- 
tionship between topoisomerase II content and cell prolifera- 
tion using a specific antibody probe. 
We have now shown that topoisomerase II is present in 
stoichiometric amounts in nuclei of  proliferating cells. When 
cells cease dividing the enzyme is rapidly lost. The mecha- 
nism of removal of topoisomerase II from nonproliferating 
cells is unknown. Given our results that virtually all topo- 
isomerase II-negative MSB-1 cells had a G1 DNA content 
(12),  it is tempting to speculate that the enzyme might be 
degraded at a  specific point during G1, perhaps as part of 
the progressive chromosome decondensation that precedes 
DNA replication (40). Our analysis of lymphocyte activation 
suggests that the enzyme might be synthesized in a cell cycle- 
regulated manner, with synthesis coupled to DNA replica- 
tion. In this case, no special mechanism need be invoked to 
explain the enzyme loss from nonproliferating cells; the fail- 
ure to reenter a new S-phase would be sufficient. An impor- 
tant test of this model will be a detailed analysis of  the synthe- 
sis  and  stability of topoisomerase II across the cell cycle 
(Heck, M. M. S. and W. C. Earnshaw, manuscript in prepa- 
ration). 
What effect would variation of topoisomerase II levels be 
expected to have on the organization and activity of the ge- 
nome? The avian erythroid cells provide an excellent oppor- 
tunity to address this question, since we have shown that ma- 
ture erythrocytes contain, if any, <300 copies of the enzyme 
per cell. Cook and Brazell (5) compared the DNA domain 
organization of embryonic and  adult  avian  red  cells.  By 
measuring  the  superhelicity of the  DNA  after gentle de- 
histonization and centrifugation in sucrose gradients,  they 
concluded that significant alterations of this organization oc- 
cur during erythropoiesis. Experiments such as these were 
the basis of the first proposals that the genome of both pro- 
karyotes  and  eukaryotes  is  packaged  into  topologically 
closed domains in vivo (2, 5). Cook and Brazell (5) observed 
a steady decrease in the compactness of the genome from 5 d 
(the earliest sample studied) onward during embryogenesis. 
In addition, they found that, unlike DNA from all growing 
cells tested, the DNA of adult erythrocytes  behaved as though 
it  was  topologically  unconstrained.  Subsequent  workers 
found that a nuclear matrix fraction cannot be obtained from 
mature avian erythrocytes (29). 
When taken together with our results, these observations 
suggest that topoisomerase II might be involved in establish- 
ment or maintenance of the topological domains. However, 
considerably more work must be done to test this hypothesis, 
as the above experiments are open to several alternative ex- 
planations. For example, the results of Cook and Brazell (5) 
could simply arise from the appearance of nucleases in later 
erythroid cells. In addition, Cook and Brazell (5) did detect 
some topologically closed domains at times when we have 
shown the topoisomerase II content of  the cells to be virtually 
nil (at 12 and 18 d, respectively). Finally, it is not clear that 
topoisomerase II is itself required for stability of the nuclear 
matrix fraction, since many other nonhistone proteins are 
also lost during erythropoiesis (41). 
The use of developmental systems has enabled us to clarify 
certain aspects of the relationship between topoisomerase II 
and genome activity in higher eukaryotes. First,  we have 
shown that high levels of transcription occur in myotubes, in 
the absence of detectable amounts of the enzyme. This con- 
clusion  was  derived both  from  sensitive  immunofluores- 
cence experiments and from analysis of single myotubes by 
simultaneous autoradiography and immunolabeling. The ob- 
servation is not peculiar to myotubes, since we also found 
that  hepatocyte  nuclei  lack  detectable  topoisomerase  II 
antigen (data not shown). We interpret these results to indi- 
cate that large amounts of topoisomerase II are not required 
for maintenance of ongoing transcription. It is possible that 
the enzyme is required for the establishment of transcrip- 
tional activity, a process that presumably occurred in myo- 
blasts before fusion. A similar conclusion was also reached 
through genetic analysis of yeasts, where mutants lacking 
topoisomerase II were found to traverse the cell cycle up to 
mitosis (6, 19, 24, 53). The developmental approach has the 
advantage, however, that the conclusions derive from obser- 
vation of unperturbed (wild type) cells. 
We have shown that when a naturally arrested population 
of peripheral blood lymphocytes commences proliferation, 
topoisomerase II is expressed concomitant with the onset of 
DNA synthesis. We could find no instances of accumulation 
of topoisomerase II before the onset of replication, suggest- 
ing that the enzyme is unlikely to be a substantial part of any 
preinitiation complex (unless addition of the enzyme is rate- 
limiting).  We also  found few,  if any,  instances of cells in 
which replication was observed in the absence of topoiso- 
merase II antigen.  It is therefore tempting to assume that 
topoisomerase II begins  to function enzymatically during 
replication, since synthesis of the enzyme and the DNA ap- 
pear to be so tightly coupled. 
Alternatively, it is possible that the appearance of the en- 
zyme during S phase reflects an "imprinting" of the mitotic 
chromosome organization during replication.  That is,  the 
enzyme might be positioned during replication at the sites 
where it acts during mitosis. Nelson et al. (36) have recently 
demonstrated a close association between the enzyme and 
newly replicated DNA. 
The above observations are consistent with the proposal 
Heck  and  Earnshaw  Topoisomerase  11: A Specific  Marker for Cell Proliferation  2579 that a major role of topoisomerase II in higher eukaryotes  is 
to disjoin the sister chromatids at mitosis (49).  Preliminary 
results  measuring drug-induced DNA cleavage  suggest that 
the enzyme activity  increases significantly  at mitosis (15). 
The large amounts of enzyme present, and its location at the 
base of radial loops in mitotic chromosomes (9) suggest that 
decatenation of chromatin  loops may in part be regulated by 
positioning the enzyme at appropriate  sites in the chromo- 
some structure. 
Regardless  of the possible role(s) of topoisomerase II in 
vivo, we have shown that the level of this protein appears to 
be a sensitive indication of the proliferative state of a given 
cell. 
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